|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Salvesen HB, Haldorsen IS and Trovik J:
Markers for individualised therapy in endometrial carcinoma. Lancet
Oncol. 13:e353–e361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Setiawan VW, Yang HP, Pike MC, McCann SE,
Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, et al:
Type I and II endometrial cancers: Have they different risk
factors? J Clin Oncol. 31:2607–2618. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chuffa LG, Lupi-Júnior LA, Costa AB,
Amorim JP and Seiva FR: The role of sex hormones and steroid
receptors on female reproductive cancers. Steroids. 118:93–108.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenfeld MG and Glass CK: Coregulator
codes of transcriptional regulation by nuclear receptors. J Biol
Chem. 276:36865–36868. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Banno K, Yanokura M, Kisu I, Yamagami W,
Susumu N and Aoki D: MicroRNAs in endometrial cancer. Int J Clin
Oncol. 18:186–192. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bao W, Wang HH, Tian FJ, He XY, Qiu MT,
Wang JY, Zhang HJ, Wang LH and Wan XP: A TrkB-STAT3-miR-204-5p
regulatory circuitry controls proliferation and invasion of
endometrial carcinoma cells. Mol Cancer. 12:1552013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen L, Li ZY, Xu SY, Zhang XJ, Zhang Y,
Luo K and Li WP: Upregulation of miR-107 inhibits glioma
angiogenesis and VEGF expression. Cell Mol Neurobiol. 36:113–120.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu C, Xie Z and Peng Q: MiRNA-107 enhances
chemosensitivity to paclitaxel by targeting antiapoptotic factor
Bcl-w in non small cell lung cancer. Am J Cancer Res. 7:1863–1873.
2017.PubMed/NCBI
|
|
13
|
Creasman W: Revised FIGO staging for
carcinoma of the endometrium. Int J Gynaecol Obstet. 105:1092009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bao W, Qiu H, Yang T, Luo X, Zhang H and
Wan X: Upregulation of TrkB promotes epithelial-mesenchymal
transition and anoikis resistance in endometrial carcinoma. PLoS
One. 8:e706162013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen J, Zhou X, Xiao Q, Wang T, Shao G, Li
Y and Zhang Z: MiR-107 suppresses cell proliferation and tube
formation of Ewing sarcoma cells partly by targeting HIF-1β. Hum
Cell. 31:42–49. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Chen F, Zhao M, Yang Z, Zhang S,
Ye L, Gao H and Zhang X: MiR-107 suppresses proliferation of
hepatoma cells through targeting HMGA2 mRNA 3′UTR. Biochem Biophys
Res Commun. 480:455–460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mercatelli N, Coppola V, Bonci D, Miele F,
Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria
R, et al: The inhibition of the highly expressed miR-221 and
miR-222 impairs the growth of prostate carcinoma xenografts in
mice. PLoS One. 3:e40292008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yeramian A, Moreno-Bueno G, Dolcet X,
Catasus L, Abal M, Colas E, Reventos J, Palacios J, Prat J and
Matias-Guiu X: Endometrial carcinoma: Molecular alterations
involved in tumor development and progression. Oncogene.
32:403–413. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schouten LJ, Goldbohm RA and van den
Brandt PA: Anthropometry, physical activity, and endometrial cancer
risk: Results from the Netherlands cohort study. Int J Gynecol
Cancer. 16 Suppl 2:S4922006. View Article : Google Scholar
|
|
21
|
Dedes KJ, Wetterskog D, Ashworth A, Kaye
SB and Reis-Filho JS: Emerging therapeutic targets in endometrial
cancer. Nat Rev Clin Oncol. 8:261–271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen WY: Exogenous and endogenous hormones
and breast cancer. Best Pract Res Clin Endocrinol Metab.
22:573–585. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chuffa LG, Seiva FR, Fávaro WJ, Amorim JP,
Teixeira GR, Mendes LO, Fioruci-Fontanelli BA, Pinheiro PF,
Martinez M and Martinez FE: Melatonin and ethanol intake exert
opposite effects on circulating estradiol and progesterone and
differentially regulate sex steroid receptors in the ovaries,
oviducts, and uteri of adult rats. Reprod Toxicol. 39:40–49. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lebeau A, Grob T, Holst F,
Seyedi-Fazlollahi N, Moch H, Terracciano L, Turzynski A, Choschzick
M, Sauter G and Simon R: Oestrogen receptor gene (ESR1)
amplification is frequent in endometrial carcinoma and its
precursor lesions. J Pathol. 216:151–157. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jongen V, Briët J, de Jong R, ten Hoor K,
Boezen M, van der Zee A, Nijman H and Hollema H: Expression of
estrogen receptor-alpha and -beta and progesterone receptor-A and
-B in a large cohort of patients with endometrioid endometrial
cancer. Gynecol Oncol. 112:537–542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rahman MT, Nakayama K, Rahman M, Ishikawa
M, Katagiri H, Katagiri A, Ishibashi T, Sato E, Iida K, Ishikawa N,
et al: ESR1 gene amplification in endometrial carcinomas: A
clinicopathological analysis. Anticancer Res. 33:3775–3781.
2013.PubMed/NCBI
|
|
27
|
Ohshiro K, Mudvari P, Meng QC, Rayala SK,
Sahin AA, Fuqua SA and Kumar R: Identification of a novel estrogen
receptor-alpha variant and its upstream splicing regulator. Mol
Endocrinol. 24:914–922. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Giacinti L, Claudio PP, Lopez M and
Giordano A: Epigenetic information and estrogen receptor alpha
expression in breast cancer. Oncologist. 11:1–8. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pelekanou V, Kampa M, Gallo D, Notas G,
Troullinaki M, Duvillier H, Jacquot Y, Stathopoulos EN, Castanas E
and Leclercq G: The estrogen receptor alpha-derived peptide ERα17p
(P295-T311) exerts pro-apoptotic actions in
breast cancer cells in vitro and in vivo, independently from their
ERα status. Mol Oncol. 5:36–47. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boren T, Xiong Y, Hakam A, Wenham R, Apte
S, Wei Z, Kamath S, Chen DT, Dressman H and Lancaster JM: MicroRNAs
and their target messenger RNAs associated with endometrial
carcinogenesis. Gynecol Oncol. 110:206–215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu W, Lin Z, Zhuang Z and Liang X:
Expression profile of mammalian microRNAs in endometrioid
adenocarcinoma. Eur J Cancer Prev. 18:50–55. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chung TK, Cheung TH, Huen NY, Wong KW, Lo
KW, Yim SF, Siu NS, Wong YM, Tsang PT, Pang MW, et al: Dysregulated
microRNAs and their predicted targets associated with endometrioid
endometrial adenocarcinoma in Hong Kong women. Int J Cancer.
124:1358–1365. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hiroki E, Akahira J, Suzuki F, Nagase S,
Ito K, Suzuki T, Sasano H and Yaegashi N: Changes in microRNA
expression levels correlate with clinicopathological features and
prognoses in endometrial serous adenocarcinomas. Cancer Sci.
101:241–249. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen L, Zhang R, Li P, Liu Y, Qin K, Fa
ZQ, Liu YJ, Ke YQ and Jiang XD: P53-induced microRNA-107 inhibits
proliferation of glioma cells and down-regulates the expression of
CDK6 and Notch-2. Neurosci Lett. 534:327–332. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Takahashi Y, Forrest AR, Maeno E,
Hashimoto T, Daub CO and Yasuda J: MiR-107 and MiR-185 can induce
cell cycle arrest in human non small cell lung cancer cell lines.
PLoS One. 4:e66772009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li X, Zhang Y, Shi Y, Dong G, Liang J, Han
Y, Wang X, Zhao Q, Ding J, Wu K, et al: MicroRNA-107, an oncogene
microRNA that regulates tumour invasion and metastasis by targeting
DICER1 in gastric cancer. J Cell Mol Med. 15:1887–1895. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Martello G, Rosato A, Ferrari F, Manfrin
A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T,
et al: A MicroRNA targeting dicer for metastasis control. Cell.
141:1195–1207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou C, Li G, Zhou J, Han N, Liu Z and Yin
J: miR-107 activates ATR/Chk1 pathway and suppress cervical cancer
invasion by targeting MCL1. PLoS One. 9:e1118602014. View Article : Google Scholar : PubMed/NCBI
|
